Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Type 1 diabetes, as an autoimmune disease, presents several islet cell-specific autoantibodies such as islet cell antibody (ICA), anti-insulin, anti-glutamic acid decarboxylase (GAD) and the antibody (Ab) against tyrosine phosphatase (
PTP
)-like protein known as ICA-512 (IA-2). In order to determine the frequency of the anti-GAD and anti-IA-2 autoantibodies in Brazilian
type 1 diabetes
patients we studied 35 diabetes mellitus (DM) type 1 patients with recent-onset disease (</=12 months) and 37
type 1 diabetes
patients with long-duration diabetes (>12 months) who were compared to 12 children with normal fasting glucose. Anti-GAD65 and anti-IA-2 autoantibodies were detected with commercial immunoprecipitation assays. The frequency of positive results in recent-onset DM type 1 patients was 80.0% for GADAb, 62.9% for IA-2Ab and 82.9% for GADAb and/or IA-2Ab. The long-duration
type 1 diabetes
subjects presented frequencies of 54.1% for GADAb and IA-2Ab, and 67.5% for GAD and/or IA-2 antibodies. The control group showed no positive cases. Anti-GAD and IA-2 assays showed a high frequency of positivity in these Brazilian
type 1 diabetes
patients, who presented the same prevalence as a Caucasian population.
...
PMID:Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients. 1051 Feb 54
The closely related mammalian proteins IA-2 and phogrin are protein tyrosine phosphatase-like receptor proteins spanning the membrane of dense core vesicles of neuroendocrine tissues. They are of interest as molecular components of the secretory machinery and as major targets of autoimmunity in
type I diabetes mellitus
. The Caenorhabditis elegans genome has a single copy of an IA-2/phogrin homolog ida-1 III (islet cell diabetic autoantigen), which encodes the ida-1 (B0244.2) gene product as a series of 12 exons over a 10-kb region of chromosome III. The full-length sequence of the ida-1 cDNA encoded a 767-amino acid type 1 transmembrane protein of 87 kDa. The
PTP
catalytic site consensus sequence of IDA-1, like IA-2 and phogrin, diverged and would not be active. Expression of green fluorescent protein (GFP) under the ida-1 gene promoter showed activity in a subset of around 30 neurons with sensory functions and the uv1 cells of the vulva in hermaphrodites. Males showed additional expression in male-specific neurons. In situ experiments in rat brain showing the distribution of IA-2 and phogrin suggested a complimentary and overlapping pattern compared with the proprotein convertases PC1 and PC2. In C. elegans, IDA-1-expressing cells comprised a subset of those expressing the PC2 homolog KPC-2 (C51E3. 7), consistent with IDA-1 being a component of neuropeptide-containing dense core vesicles. The results support the hypothesis that C. elegans IDA-1 is the functional homolog of IA-2 and phogrin in mammals. Analysis of the function of IDA-1 should contribute to our understanding of the function of these proteins in signal transduction, vesicle locomotion, and exocytosis.
...
PMID:IDA-1, a Caenorhabditis elegans homolog of the diabetic autoantigens IA-2 and phogrin, is expressed in peptidergic neurons in the worm. 1108 94
Different autoimmune mechanisms may be involved in childhood- and adult-onset
type 1 diabetes
. Our aim was to explore the differences in IA-2 autoantibody epitope recognition between childhood- and adult-onset
type 1 diabetes
. Therefore, in vitro synthesized radiolabeled IA-2ic (amino acid 601-979), IA-2JM (amino acid 557-629), and IA-2PTP (amino acid 630-979) were used to analyze the IA-2 autoantibody epitope specificities in 93 patients with new-onset
type 1 diabetes
. Among 93 patients with
type 1 diabetes
the prevalences of autoantibodies to GAD, IA-2ic, and insulin were 69.9%, 58.1%, and 45.2%, respectively. The prevalence of IA-2ic autoantibodies in patients with childhood-onset
type 1 diabetes
(aged <or=18 years, n = 60) was significantly higher than that in patients with adult-onset diabetes (68.3 vs. 36.4%, P < 0.002). Ninety-two percent of type 1 diabetic patients positive for IA-2ic autoantibodies recognized the
PTP
domain of IA-2, whereas 8% reacted with the JM region only. Among 60 patients with childhood-onset
type 1 diabetes
, 2% recognized the JM region only, 48% bound the
PTP
domain of IA-2 only, and 18% recognized both JM and
PTP
epitopes. Among 33 patients with adult-onset diabetes, 9% recognized the IA-2JM only, 18% bound the IA-2PTP only, and 9% recognized both the IA-2JM and the IA-2PTP. IA-2PTP autoantibodies were prevalent in patients with childhood-onset
type 1 diabetes
. By contrast, the proportion of patients with the IA-2JM autoantibody only in
type 1 diabetes
who were positive for IA-2ic autoantibodies was significantly higher in adult-onset than in childhood-onset diabetes (P < 0.05). These results demonstrate that autoantibody recognition of the IA-2 epitope is distinct in childhood-onset and adult-onset
type 1 diabetes
.
...
PMID:Distinct IA-2 autoantibody epitope recognition between childhood-onset and adult-onset type 1 diabetes. 1202 Nov 14
A hybridoma secreting a human monoclonal autoantibody to the islet cell autoantigen IA-2 was prepared from peripheral lymphocytes of a patient with
type 1 diabetes
and Graves' disease using EBV infection followed by fusion with a mouse/human hybrid cell line. The monoclonal antibody (M13) is an IgG1/kappa and in an immunofluorescence test M13 at 1 microg/mL showed islet cell antibody reactivity equivalent to 40 JDF units. M13 IgG bound (35)S-labelled IA-2 (26% at 100 microg/mL) and (125)I-labelled IA-2 (34% at 100 microg/mL) in an immunoprecipitation assay and reacted well with IA-2 in western blotting analysis. Amino acids 777-808 in the
PTP
domain of IA-2 were found to be important for M13 binding in an analysis using modified (35)S-labelled IA-2 proteins. M13 V region genes were from VH1-3, D3-22, JH4b, VKI DPK8/Vd+ and JK3 genes and showed a high replacement/silent mutation ratio for both the heavy (11.0) and the light (6.0) chain genes. Mouse monoclonal antibodies (mMAbs) reactive with at least three different epitopes within IA-2 aa 604-686 corresponding to the juxtamembrane domain were also obtained. F(ab')(2) or Fab from the mMAbs inhibited serum IA-2 autoantibody binding to IA-2 in 20/22 diabetic sera whereas M13 F(ab')(2) caused inhibition in only 6/22 sera. M13 is representative of some patient serum IA-2 autoantibodies and as such provides a useful tool to study autoimmune responses to IA-2.
...
PMID:Isolation and characterisation of a human monoclonal autoantibody to the islet cell autoantigen IA-2. 1586 63